Johnson & Johnson (JNJ) Receives Price Target

Johnson & Johnson (JNJ) : The highest short term price target forecast on Johnson & Johnson (JNJ) is $142 and the lowest target price is $93. A total of 13 equity analysts are currently covering the company. The average price of all the analysts is $125 with a standard deviation of $14.48.

Johnson & Johnson (JNJ) : 7 brokerage houses believe that Johnson & Johnson (JNJ) is a Strong Buy at current levels. 2 Analyst considers the fundamentals to be worthy of a Buy recommendation. 8 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Johnson & Johnson (JNJ). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 18 Wall Street Analysts endorse the stock as a Buy with a rating of 2.22.


Also, Major Brokerage house, Jefferies maintains its ratings on Johnson & Johnson (NYSE:JNJ). In the latest research report, Jefferies raises the target price from $113 per share to $119 per share. According to the latest information available, the shares are now rated Hold by the analysts at the agency. The rating by the firm was issued on August 4, 2016.

Johnson & Johnson (NYSE:JNJ): The stock opened at $119.19 on Thursday but the bulls could not build on the opening and the stock topped out at $119.39 for the day. The stock traded down to $118.60 during the day, due to lack of any buying support eventually closed down at $119.08 with a loss of -0.22% for the day. The stock had closed at $119.34 on the previous day. The total traded volume was 4,551,792 shares.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.